Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. - Wikidata - wikimedia - TriplyDB

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

http://www.wikidata.org/entity/Q40498974

about

The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity Combination strategies enhance oncolytic virotherapy.Leveraging natural killer cells for cancer immunotherapy.The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities.Redox control of cancer cell destruction.Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.Potential of oncolytic viruses in the treatment of multiple myeloma.Tumor immunotherapy: New aspects of natural killer cells.Induction of Oxidative DNA Damage in Bovine Herpesvirus 1 Infected Bovine Kidney Cells (MDBK Cells) and Human Tumor Cells (A549 Cells and U2OS Cells)

P2860

Q33703068-FCE84397-A7E1-4E92-BC23-4EFF720E8D08 Q39020795-7731D47F-B3D6-4CE9-B2E6-FD0D46EAF2C8 Q40072916-9B0E77D7-F648-49D9-9A10-E8E32DE5AB7F Q40081751-4C785F17-252E-4F0D-B354-805AEC2BB276 Q40471303-C8DA7162-AE96-491A-9587-F9DBED02622B Q42338756-C1961162-5993-41AE-9813-D9AFC91FDA4E Q43865719-563DBA34-C1E4-4C71-9140-EB0AED06BC03 Q48000346-34F777A2-AB09-415C-866F-52FA0D33D693 Q51748168-FAC4D017-9890-4C61-9003-DA37AD244655 Q52312118-3264724C-62CC-4725-86C3-45162F553885 Q52653307-DED96185-7B06-455E-9C92-BD914BC1940E Q52674773-D5022D73-1023-46EF-8FC6-ABE71CB58528 Q55107050-69BC8F99-FAA9-41D0-A093-969F765F3B77 Q56561196-5F2F7022-2BAD-4C22-831F-A6D03418EDD1

P2860

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

http://www.wikidata.org/entity/Q40498974

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

@en

type

label

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

@en

prefLabel

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

@en

P1433

Q40498974-C243EB26-AD30-467B-B71A-3ED97C55816D

P1476

Q40498974-E62A2956-E6F3-460D-99BC-F109E5B447C5

P2093

Q40498974-16560614-9E14-4D27-A6CA-24943094BE4C

Q40498974-198850E0-710D-46B2-948E-43F752260655

Q40498974-3C92BE03-55B5-4857-AD59-2BA5D0FD032D

Q40498974-4E1EF0C5-934C-470C-AC60-11334947D15C

Q40498974-4E84F239-4A5C-4E60-BF0B-B7AE82687209

Q40498974-6DCAD980-CBB5-4FA4-8290-A003AAE0D97B

Q40498974-727BFA94-26F9-4422-90D5-F2D84C5C2764

Q40498974-960C9DF1-0FD2-4925-A004-A15E69FF969E

Q40498974-981491D8-E32F-497C-8203-16CF49130838

Q40498974-9FC253A0-88BB-411F-8CBB-F0B780C903D3

P2860

Q40498974-01A34DA0-6849-4794-8713-A897FC947447

Q40498974-0A79AE46-BB33-4642-BFDA-B35193269298

Q40498974-11AAF7A0-CD8F-4D6A-9A55-2575C7D0A11F

Q40498974-150B3F30-CFC5-4791-A6EC-E4D44747B800

Q40498974-15A50435-062C-432C-A818-AAE1113D80CF

Q40498974-1CC0FA98-D03B-4B34-9BA2-A3C609123F30

Q40498974-261C782B-6458-44BB-B204-406355095736

Q40498974-346B285E-E136-4132-9960-53A24787A466

Q40498974-3683B524-320E-4DDF-A780-ADA66AEAC58A

Q40498974-3882A209-0A17-4D62-BB92-50027529838B

P304

Q40498974-298ADCAB-7BCC-44EA-8D67-13D970CC9912

P31

Q40498974-6F0BCC02-B58E-4B9A-8C08-E14A671C32AF

P356

Q40498974-A128EAEF-D6F3-495B-A041-73D164661E4F

P407

Q40498974-AD7472B1-71FD-41E2-8D8B-44795CA4B4BE

P433

Q40498974-B0A6829B-D447-4814-933D-C0DFA9A71D2F

P478

Q40498974-E1CE3628-7C8A-48E2-A64D-6417440BCCA6

P50

Q40498974-7BF2F442-A105-49F9-8357-4A3E34E1D467

P577

Q40498974-92AF94E3-AFEA-4DB2-A0D4-549011BD5175

P698

Q40498974-77FA705A-E725-4B0A-AB56-E547760BA146

P921

Q40498974-3FEFF507-8F47-4739-BA90-49BBBB8B4229

P932

Q40498974-988B5805-A6E8-4B4E-BCDB-F24C8BD1631E

P356

1078-0432.CCR-16-1003

P1433

Clinical Cancer Research

P1476

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

@en

P2093

Alena Cristina Jaime-Ramirez

http://www.w3.org/2001/XMLSchema#string

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

Brian S Hurwitz

http://www.w3.org/2001/XMLSchema#string

Chelsea Bolyard

http://www.w3.org/2001/XMLSchema#string

Hongsheng Dai

http://www.w3.org/2001/XMLSchema#string

Jeffrey Wojton

http://www.w3.org/2001/XMLSchema#string

Ji Young Yoo

http://www.w3.org/2001/XMLSchema#string

Jianhua Yu

http://www.w3.org/2001/XMLSchema#string

Jianying Zhang

http://www.w3.org/2001/XMLSchema#string

Jun-Ge Yu

http://www.w3.org/2001/XMLSchema#string

P2860

The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal

Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells

A receptor for phosphatidylserine-specific clearance of apoptotic cells

Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.

Necroptosis as an alternative form of programmed cell death.

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Necroptosis: the release of damage-associated molecular patterns and its physiological relevance.

Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.

P304

5265-5276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-16-1003

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Carlo Maria Croce

P577

2016-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27390350

http://www.w3.org/2001/XMLSchema#string

P921

P932

5093037

http://www.w3.org/2001/XMLSchema#string